EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Onconeural Antibodies in Metastatic Renal Cell Carcinoma: A Hypothesis-Generating Study of Anti-Hu Antibodies and Overall Survival

Edina Kovács, Márk Kozák, Ingrid Balogh, Judit Kocsis, Zsolt Horváth, Álmos Márk Kádár, Attila Tóth, Judit Boczán

Antibodies · 2026-11-06 · 15 (6) · 106

DOI: 10.3390/antib15060106 ↗
AbstractBibliografische Angaben

Abstract

Background: Onconeural antigens expressed by tumor cells may trigger the production of onconeural antibodies, which result in paraneoplastic neurological syndromes (PNS). Objectives: We investigated the presence of eight onconeural antibodies (amphiphysin, CRMP5, Nova/Ri, Cdr2/Yo, Elav/Hu, Zic4, Ma2, recoverin) and neurologic symptoms and signs in 33 metastatic renal cell carcinoma patients who started first-line therapy. Overall survival (OS) and time to treatment failure (TTF) were also determined. Methods: Sera were tested on a dot blot of purified, recombinant, human onconeural antigens. Neurologic symptoms were reviewed by a questionnaire, and signs were determined by a dedicated neurologist. OS and TTF of patients were determined by Kaplan–Meier analysis. Results: 51% of patients (17 of 33) harbored at least one onconeural antibody, 36% of patients had multiple antibodies. Two patients with cerebellar signs and three patients with signs of polyneuropathy had onconeural antibodies, suggesting a definite PNS. Six additional patients with polyneuropathy and without onconeural antibodies might have possible PNS. OS was significantly longer in patients harboring the anti-Hu antibody (n = 14) compared to those without it (n = 19) (median survival was 745 and 135 weeks, respectively). Conclusions: We have found that the occurrence of onconeural antibodies is relatively high in metastatic RCC, not reported previously. A significant percentage of these patients have neurological symptoms with a probable paraneoplastic background, which may have a detrimental impact on their quality of life. Anti-Hu antibody was identified most frequently. Our preliminary data show that the presence of anti-Hu antibody correlates with better prognosis and survival, suggesting the beneficial role of activated autoimmunity. In the era of frontline immune checkpoint inhibitor (ICI) therapy of RCC, it would be strongly encouraged to further explore the prognostic and potentially predictive role of anti-Hu antibody.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →